COHR vs NOVT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COHR and NOVT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COHR and NOVT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Coherent Corp, formerly II-VI and now trading as COHR on the NYSE, makes lasers, optical components, and high-speed transceivers used in AI data centers, telecom networks, industrial manufacturing, and semiconductors. Its largest and fastest-growing segment is Datacenter & Communications, which supplies the 800G and emerging 1.6T optical transceivers that connect GPUs and switches inside AI clusters, alongside a smaller Industrial segment covering lasers and materials.

Full COHR guide

Novanta Inc. is a specialized technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems, which it sells to original equipment manufacturers (OEMs) in medical and advanced industrial markets worldwide. Its products include laser scanning and beam-steering systems, precision motors and encoders, machine-vision components, radio-frequency and surgical technologies, and other embedded devices that go inside customers' larger machines. The company organizes itself into two reporting segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and semiconductor and electronics manufacturing. Medical end markets represent a bit over half of revenue and advanced industrial the rest.

Full NOVT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COHR drivers: AI datacom transceiver demand; Transition to 1.6T optics.
• NOVT drivers: Medical Solutions demand; Automation and robotics.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: COHR trades at a high earnings multiple, so any slowdown in AI capital spending or a demand air pocket could hit the stock hard. For NOVT, novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COHR if you believe its drivers more; NOVT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COHR and NOVT guides.

COHR. Coherent's revenue has accelerated on AI datacenter optics demand, with the Datacenter & Communications segment making up about three quarters of sales. The stock carries a high trailing multiple that reflects rapid earnings growth expectations, so the valuation depends heavily on that growth continuing. Figures are approximate and shift with each quarterly report and market moves.

NOVT. Novanta trades at a rich valuation, with a trailing price-to-earnings ratio near 100x and a forward multiple around 41x, reflecting the market's view of it as a durable, high-margin precision-technology compounder. GAAP earnings are held down by acquisition-related amortization and stock compensation, so the company and analysts emphasize adjusted EPS and adjusted EBITDA. That premium multiple means the shares can react strongly to any change in the growth or margin trajectory.

Headline figures (approximate, July 2026): COHR shows revenue (ttm) ~$6.3B, q3 fy2026 revenue ~$1.81B (up ~21% YoY), q3 fy2026 non-gaap eps ~$1.41, q4 fy2026 revenue guidance ~$1.91B to $2.05B; NOVT shows revenue (ttm) ~$1.0 billion, q1 fy2026 revenue ~$258 million (up ~10% YoY), fy2026 revenue guidance ~$1,040-1,055 million, adjusted eps guidance (fy2026) ~$3.50-3.65.

COHR and NOVT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COHR and NOVT exposure against your real portfolio. It is not an investment adviser.